Sign In
Buy MRTX
$58.70
+0 (+0%)
At Close: Apr 19, 2024
Top stocks October 9, 2023: Tesla, Bristol Myers-Mirati, Alnylam Pharma
05:13pm, Monday, 09'th Oct 2023
Tesla (TSLA) shares are in focus as China-made EV demand drops by 10%, affecting Model 3 and Y sales. Tesla's delivery and production data declined from last quarter following a report by the China Pa
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Mirati Thera
Analysts Target Biotech Name on Buyout Buzz
03:03pm, Monday, 09'th Oct 2023
Mirati Therapeutics Inc (NASDAQ:MRTX) stock is dropping today, after news that Bristol-Myers Squibb (BMY) will acquire the company for up to $5.8 billion.
Bristol-Myers is spending $5.8 billion to buy Mirati Therapeutics
01:04pm, Monday, 09'th Oct 2023
Bristol-Myers Squibb Co (NYSE: BMY) has decided to spend up to $5.8 billion to acquire Mirati Therapeutics Inc (NASDAQ: MRTX). Shares of both companies are in the red at writing.
Bristol-Myers Squibb Buys Mirati Therapeutics to Boost Cancer Drug Portfolio
12:05pm, Monday, 09'th Oct 2023
Bristol-Myers Squibb (BMY) moved to expand its reach into cancer-fighting drugs by buying Mirati Therapeutics (MRTX) in an all-cash deal for what could total $5.8 billion.
Bristol Myers Squibb to buy cancer drugmaker Mirati Therapeutics in up to $5.8B deal
11:40am, Monday, 09'th Oct 2023
Bristol Myers Squibb will buy Mirati Therapeutics in a deal worth up to $5.8 billion, or $58 per share, the biopharmaceutical company announced Sunday.
Bristol-Myers Squibb to acquire Mirati in deal worth up to $5.8B
10:48am, Monday, 09'th Oct 2023
Bristol-Myers Squibb (BMY) agreed to buy cancer drugmaker Mirati Therapeutics (MRTX) for up to $5.8 billion. The deal will help Bristol-Myers Squibb bring new drugs into their pipeline as some of thei
Mirati Stock Falls as Bristol Myers to Buy Oncology Developer for Up to $5.8 Billion
05:27am, Monday, 09'th Oct 2023
The acquisition will help boost revenue by offsetting upcoming competition from generics for Bristol Myers Squibb's best-selling products.
Bristol Myers Squibb to buy Mirati Therapeutics in deal worth up to $5.8 billion
07:34pm, Sunday, 08'th Oct 2023
Bristol Myers Squibb Co. said Sunday it will buy Mirati Therapeutics Inc. in a deal valued at up to $5.8 billion.
Bristol Myers Squibb to Acquire Mirati Therapeutics in Deal Worth Up to $5.8 Billion
06:12pm, Sunday, 08'th Oct 2023
The deal expands the pharmaceutical company's portfolio of cancer drugs.
Bristol-Myers Squibb to acquire Mirati in a $4.8 billion deal
05:56pm, Sunday, 08'th Oct 2023
Bristol-Myers Squibb is set to acquire cancer drugmaker Mirati Therapeutics for $58 per share in cash, representing $4.8 billion equity value.
Mirati (MRTX) Surges 45% as Sanofi Reportedly Eyes Buyout
12:47pm, Friday, 06'th Oct 2023
A Bloomberg article suggests that pharma giant Sanofi (SNY) is exploring a potential acquisition deal for small cancer drugmaker Mirati Therapeutics (MRTX).
Mirati To Present Updated Clinical Data at ESMO Congress 2023
04:30pm, Wednesday, 27'th Sep 2023
Late-Breaking KRYSTAL-7 data demonstrates compelling efficacy and safety of adagrasib in combination with pembrolizumab in 1L NSCLC Data follows recent inclusion of the adagrasib in combination with
Mirati (MRTX) Soars 12.3%: Is Further Upside Left in the Stock?
06:01am, Friday, 22'nd Sep 2023
Mirati (MRTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in t
SAN DIEGO , Aug. 21, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. ® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced a presentation of two-year follow-up from a pooled anal
